-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

Benzinga·09/14/2026 17:14:06
Listen to the news
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.